Evaluation of Electrocardiographic and Echocardiographic Findings In Patients Diagnosed with Polycythemia Vera and Essential Thrombocythemia
Abstract
Background/Aims: Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative diseases. Along with the increase in myeloproliferative cell lines, they can cause various clinical outcomes such as arterial and venous thrombosis, pulmonary hypertension, and myocardial infarction. This study was designed to evaluate the cardiac effects of these diseases via electrocardiography and echocardiography.
Methods: A total of 50 patients with a diagnosis of PV, 50 patients with a diagnosis of ET, and 50 healthy individuals as a control group were included in this study. Data on patient demographics were recorded in all subjects. All patients and control subjects had electrocardiography (ECG) recordings and routine transthoracic echocardiographic examination. Pulse wave velocity (PWV) was assessed with a Holter blood pressure device.
Results: In total, 50 PV patients, 50 ET patients, and 50 control group were included in the study. The demographic characteristics of the PV, ET and control groups were similar. The PR interval was significantly shorter in control subjects than in PV and ET patients (p:0.007, p:0.024). Although the measured values were within normal limits, diastolic posterior wall thickness was significantly lower in the control group compared to PV and ET patients (p:0.019, p:0.009). PWV was significantly higher in ET patients compared to the control group (p:0.012).
Conclusion: In this study, evaluating the effects of PV and ET on electrocardiography and transthoracic echocardiography; ECG parameters used to predict ventricular arrhythmias (QT, QTc, Tp-Te, Tp-Te/QT) and Pulmonary Artery Pressure showed no significant change, in opposition to existing literature. Nonetheless, similar to previous publications, PV and ET were found to negatively affect the diastolic function parameters on transthoracic echocardiography. While the aortic stiffness was significantly higher in ET patients compared to the control group, no significant difference was noted between PV patients and control subjects in terms of aortic stiffness.
Keywords
Polycythemia vera, Essential thrombocythemia, electrocardiography, echocardiography
References
- Spivak JL, Barosi G, Tognoni G, Barbui T, Finazzi G, Marchioli R, et al. Chronic myeloproliferative disorders. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2003.
- Demircioglu S, Budancamanak S, Dogan A. Can Serum B12 Level Be Used As An Effective Differential Criterion in Differential Diagnosis of Primary and Secondary Polycythemia. Selcuk Tip Dergisi. 2020 Mar 1;1(36):22–6.
- Gökgöz Z, Özdemirkıran F, Cömert M, Saydam G. Kronik Miyeloproliferatif Neoplazi Tanılı 114 Hastanın İncelemesi. Selçuk Tıp Dergisi. 2014;30(4):169–71.
- Watson K V., Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol. 1993;198–203.
- Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia. 2013;
- Vianello F, Battisti A, Cella G, Marchetti M, Falanga A. Defining the thrombotic risk in patients with myeloproliferative neoplasms. TheScientificWorldJournal. 2011.
- Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. British Journal of Haematology. 2005. p. 275–90.
- Besses C, Cervantes F, Pereira A, Florensa L, Solé F, Hernández-Boluda JC, et al. Major vascular complications in essential thrombocythemia: A study of the predictive factors in a series of 148 patients. Leukemia. 1999;
- Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis. New England Journal of Medicine. 1995;
- Gao W, Shen W, Luo X, Shi H, Jiang X, Pan J. ST-segment elevation myocardial infarction in patient with essential thrombocythemia without associated risk. Int J Cardiol. 2015;